Detecting High-Dose Methotrexate-Induced Brain Changes in Pediatric and Young Adult Cancer Survivors Using [ 18 F]FDG PET/MRI: A Pilot Study
Significant improvements in treatments for children with cancer have resulted in a growing population of childhood cancer survivors who may face long-term adverse outcomes. Here, we aimed to diagnose high-dose methotrexate-induced brain injury on [ F]FDG PET/MRI and correlate the results with cognit...
Gespeichert in:
Veröffentlicht in: | Journal of Nuclear Medicine 2024-06, Vol.65 (6), p.864-871 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 871 |
---|---|
container_issue | 6 |
container_start_page | 864 |
container_title | Journal of Nuclear Medicine |
container_volume | 65 |
creator | Baratto, Lucia Singh, Shashi B Williams, Sharon E Spunt, Sheri L Rosenberg, Jarrett Adams, Lisa Suryadevara, Vidyani Iv, Michael Daldrup-Link, Heike |
description | Significant improvements in treatments for children with cancer have resulted in a growing population of childhood cancer survivors who may face long-term adverse outcomes. Here, we aimed to diagnose high-dose methotrexate-induced brain injury on [
F]FDG PET/MRI and correlate the results with cognitive impairment identified by neurocognitive testing in pediatric cancer survivors.
In this prospective, single-center pilot study, 10 children and young adults with sarcoma (
= 5), lymphoma (
= 4), or leukemia (
= 1) underwent dedicated brain [
F]FDG PET/MRI and a 2-h expert neuropsychologic evaluation on the same day, including the Wechsler Abbreviated Scale of Intelligence, second edition, for intellectual functioning; Delis-Kaplan Executive Function System (DKEFS) for executive functioning; and Wide Range Assessment of Memory and Learning, second edition (WRAML), for verbal and visual memory. Using PMOD software, we measured the SUV
, cortical thickness, mean cerebral blood flow (CBF
), and mean apparent diffusion coefficient of 3 different cortical regions (prefrontal cortex, cingulate gyrus, and hippocampus) that are routinely involved during the above-specified neurocognitive testing. Standardized scores of different measures were converted to
scores. Pairs of multivariable regression models (one for
scores < 0 and one for
scores > 0) were fitted for each brain region, imaging measure, and test score. Heteroscedasticity regression models were used to account for heterogeneity in variances between brain regions and to adjust for clustering within patients.
The regression analysis showed a significant correlation between the SUV
of the prefrontal cortex and cingulum and DKEFS-sequential tracking (DKEFS-TM4)
scores (
= 0.003 and
= 0.012, respectively). The SUV
of the hippocampus did not correlate with DKEFS-TM4
scores (
= 0.111). The SUV
for any evaluated brain regions did not correlate significantly with WRAML-visual memory (WRAML-VIS)
scores. CBF
showed a positive correlation with SUV
(
= 0.56,
= 0.01). The CBF
of the cingulum, hippocampus, and prefrontal cortex correlated significantly with DKEFS-TM4 (all
< 0.001). In addition, the hippocampal CBF
correlated significantly with negative WRAML-VIS
scores (
= 0.003).
High-dose methotrexate-induced brain injury can manifest as a reduction in glucose metabolism and blood flow in specific brain areas, which can be detected with [
F]FDG PET/MRI. The SUV
and CBF
of the prefrontal cortex and cingulum can serve as q |
doi_str_mv | 10.2967/jnumed.123.266760 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11149594</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3064695446</sourcerecordid><originalsourceid>FETCH-LOGICAL-c277t-510b1ac0eb5a6922008be8502439a0bae42b358edcede3ee7acaa4073b1cc9703</originalsourceid><addsrcrecordid>eNpVkd1qGzEQhUVpSNwkD9CbIuj1OtJqpd3tTXHsODEk1OTnopQitNqJLWNLqX5M8w596Mg4De3VzDBnzhz4EPpIybBsRX22smkD_ZCWbFgKUQvyDg0oZ7zgeXqPBoQKWnBO-BH6EMKKECKapjlER6zhNactG6A_E4igo7ELfGUWy2LiAuAbiEsXPfxWEYqZ7ZOGHp97ZSweL5VdQMC5nUNvVPRGY2V7_N2l7DHq0zrisbIaPL5Lfmu2zgf8EHYPfmDa4OnP6eQSzy_uz25uZ1_wCM_N2kV8F1P_fIIOHtU6wOlrPUYP04v78VVx_e1yNh5dF7qs61hwSjqqNIGOK9GWJSFNBw0nZcVaRToFVdkx3kCfYwMDqJVWqiI166jWbU3YMfq6931K3WYns9GrtXzyZqP8s3TKyP831izlwm0lpbRqeVtlh8-vDt79ShCiXLnkbQ4tGRGVaHlViayie5X2LgQPj28vKJE7gnJPUGaCck8w33z6N9vbxV9k7AVohZkq</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3064695446</pqid></control><display><type>article</type><title>Detecting High-Dose Methotrexate-Induced Brain Changes in Pediatric and Young Adult Cancer Survivors Using [ 18 F]FDG PET/MRI: A Pilot Study</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Baratto, Lucia ; Singh, Shashi B ; Williams, Sharon E ; Spunt, Sheri L ; Rosenberg, Jarrett ; Adams, Lisa ; Suryadevara, Vidyani ; Iv, Michael ; Daldrup-Link, Heike</creator><creatorcontrib>Baratto, Lucia ; Singh, Shashi B ; Williams, Sharon E ; Spunt, Sheri L ; Rosenberg, Jarrett ; Adams, Lisa ; Suryadevara, Vidyani ; Iv, Michael ; Daldrup-Link, Heike</creatorcontrib><description>Significant improvements in treatments for children with cancer have resulted in a growing population of childhood cancer survivors who may face long-term adverse outcomes. Here, we aimed to diagnose high-dose methotrexate-induced brain injury on [
F]FDG PET/MRI and correlate the results with cognitive impairment identified by neurocognitive testing in pediatric cancer survivors.
In this prospective, single-center pilot study, 10 children and young adults with sarcoma (
= 5), lymphoma (
= 4), or leukemia (
= 1) underwent dedicated brain [
F]FDG PET/MRI and a 2-h expert neuropsychologic evaluation on the same day, including the Wechsler Abbreviated Scale of Intelligence, second edition, for intellectual functioning; Delis-Kaplan Executive Function System (DKEFS) for executive functioning; and Wide Range Assessment of Memory and Learning, second edition (WRAML), for verbal and visual memory. Using PMOD software, we measured the SUV
, cortical thickness, mean cerebral blood flow (CBF
), and mean apparent diffusion coefficient of 3 different cortical regions (prefrontal cortex, cingulate gyrus, and hippocampus) that are routinely involved during the above-specified neurocognitive testing. Standardized scores of different measures were converted to
scores. Pairs of multivariable regression models (one for
scores < 0 and one for
scores > 0) were fitted for each brain region, imaging measure, and test score. Heteroscedasticity regression models were used to account for heterogeneity in variances between brain regions and to adjust for clustering within patients.
The regression analysis showed a significant correlation between the SUV
of the prefrontal cortex and cingulum and DKEFS-sequential tracking (DKEFS-TM4)
scores (
= 0.003 and
= 0.012, respectively). The SUV
of the hippocampus did not correlate with DKEFS-TM4
scores (
= 0.111). The SUV
for any evaluated brain regions did not correlate significantly with WRAML-visual memory (WRAML-VIS)
scores. CBF
showed a positive correlation with SUV
(
= 0.56,
= 0.01). The CBF
of the cingulum, hippocampus, and prefrontal cortex correlated significantly with DKEFS-TM4 (all
< 0.001). In addition, the hippocampal CBF
correlated significantly with negative WRAML-VIS
scores (
= 0.003).
High-dose methotrexate-induced brain injury can manifest as a reduction in glucose metabolism and blood flow in specific brain areas, which can be detected with [
F]FDG PET/MRI. The SUV
and CBF
of the prefrontal cortex and cingulum can serve as quantitative measures for detecting executive functioning problems. Hippocampal CBF
could also be useful for monitoring memory problems.</description><identifier>ISSN: 0161-5505</identifier><identifier>EISSN: 1535-5667</identifier><identifier>EISSN: 2159-662X</identifier><identifier>DOI: 10.2967/jnumed.123.266760</identifier><identifier>PMID: 38575193</identifier><language>eng</language><publisher>United States: Society of Nuclear Medicine</publisher><subject>Adolescent ; Adult ; Blood flow ; Brain ; Brain - diagnostic imaging ; Brain - drug effects ; Brain injury ; Cancer ; Cancer Survivors ; Cerebral blood flow ; Child ; Children ; Cingulum ; Clinical Investigation ; Clustering ; Cognition ; Cognitive ability ; Correlation ; Diffusion coefficient ; Evaluation ; Executive function ; Female ; Fluorine isotopes ; Fluorodeoxyglucose F18 ; Glucose metabolism ; Head injuries ; Heterogeneity ; Hippocampus ; Humans ; Intelligence ; Leukemia ; Lymphoma ; Magnetic Resonance Imaging ; Male ; Memory ; Methotrexate ; Methotrexate - adverse effects ; Methotrexate - therapeutic use ; Multimodal Imaging ; Neuroimaging ; Pediatrics ; Pilot Projects ; Positron emission ; Positron emission tomography ; Prefrontal cortex ; Prospective Studies ; Regression analysis ; Regression models ; Sarcoma ; Survival ; Traumatic brain injury ; Young Adult ; Young adults</subject><ispartof>Journal of Nuclear Medicine, 2024-06, Vol.65 (6), p.864-871</ispartof><rights>2024 by the Society of Nuclear Medicine and Molecular Imaging.</rights><rights>Copyright Society of Nuclear Medicine Jun 1, 2024</rights><rights>2024 by the Society of Nuclear Medicine and Molecular Imaging. 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c277t-510b1ac0eb5a6922008be8502439a0bae42b358edcede3ee7acaa4073b1cc9703</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38575193$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Baratto, Lucia</creatorcontrib><creatorcontrib>Singh, Shashi B</creatorcontrib><creatorcontrib>Williams, Sharon E</creatorcontrib><creatorcontrib>Spunt, Sheri L</creatorcontrib><creatorcontrib>Rosenberg, Jarrett</creatorcontrib><creatorcontrib>Adams, Lisa</creatorcontrib><creatorcontrib>Suryadevara, Vidyani</creatorcontrib><creatorcontrib>Iv, Michael</creatorcontrib><creatorcontrib>Daldrup-Link, Heike</creatorcontrib><title>Detecting High-Dose Methotrexate-Induced Brain Changes in Pediatric and Young Adult Cancer Survivors Using [ 18 F]FDG PET/MRI: A Pilot Study</title><title>Journal of Nuclear Medicine</title><addtitle>J Nucl Med</addtitle><description>Significant improvements in treatments for children with cancer have resulted in a growing population of childhood cancer survivors who may face long-term adverse outcomes. Here, we aimed to diagnose high-dose methotrexate-induced brain injury on [
F]FDG PET/MRI and correlate the results with cognitive impairment identified by neurocognitive testing in pediatric cancer survivors.
In this prospective, single-center pilot study, 10 children and young adults with sarcoma (
= 5), lymphoma (
= 4), or leukemia (
= 1) underwent dedicated brain [
F]FDG PET/MRI and a 2-h expert neuropsychologic evaluation on the same day, including the Wechsler Abbreviated Scale of Intelligence, second edition, for intellectual functioning; Delis-Kaplan Executive Function System (DKEFS) for executive functioning; and Wide Range Assessment of Memory and Learning, second edition (WRAML), for verbal and visual memory. Using PMOD software, we measured the SUV
, cortical thickness, mean cerebral blood flow (CBF
), and mean apparent diffusion coefficient of 3 different cortical regions (prefrontal cortex, cingulate gyrus, and hippocampus) that are routinely involved during the above-specified neurocognitive testing. Standardized scores of different measures were converted to
scores. Pairs of multivariable regression models (one for
scores < 0 and one for
scores > 0) were fitted for each brain region, imaging measure, and test score. Heteroscedasticity regression models were used to account for heterogeneity in variances between brain regions and to adjust for clustering within patients.
The regression analysis showed a significant correlation between the SUV
of the prefrontal cortex and cingulum and DKEFS-sequential tracking (DKEFS-TM4)
scores (
= 0.003 and
= 0.012, respectively). The SUV
of the hippocampus did not correlate with DKEFS-TM4
scores (
= 0.111). The SUV
for any evaluated brain regions did not correlate significantly with WRAML-visual memory (WRAML-VIS)
scores. CBF
showed a positive correlation with SUV
(
= 0.56,
= 0.01). The CBF
of the cingulum, hippocampus, and prefrontal cortex correlated significantly with DKEFS-TM4 (all
< 0.001). In addition, the hippocampal CBF
correlated significantly with negative WRAML-VIS
scores (
= 0.003).
High-dose methotrexate-induced brain injury can manifest as a reduction in glucose metabolism and blood flow in specific brain areas, which can be detected with [
F]FDG PET/MRI. The SUV
and CBF
of the prefrontal cortex and cingulum can serve as quantitative measures for detecting executive functioning problems. Hippocampal CBF
could also be useful for monitoring memory problems.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Blood flow</subject><subject>Brain</subject><subject>Brain - diagnostic imaging</subject><subject>Brain - drug effects</subject><subject>Brain injury</subject><subject>Cancer</subject><subject>Cancer Survivors</subject><subject>Cerebral blood flow</subject><subject>Child</subject><subject>Children</subject><subject>Cingulum</subject><subject>Clinical Investigation</subject><subject>Clustering</subject><subject>Cognition</subject><subject>Cognitive ability</subject><subject>Correlation</subject><subject>Diffusion coefficient</subject><subject>Evaluation</subject><subject>Executive function</subject><subject>Female</subject><subject>Fluorine isotopes</subject><subject>Fluorodeoxyglucose F18</subject><subject>Glucose metabolism</subject><subject>Head injuries</subject><subject>Heterogeneity</subject><subject>Hippocampus</subject><subject>Humans</subject><subject>Intelligence</subject><subject>Leukemia</subject><subject>Lymphoma</subject><subject>Magnetic Resonance Imaging</subject><subject>Male</subject><subject>Memory</subject><subject>Methotrexate</subject><subject>Methotrexate - adverse effects</subject><subject>Methotrexate - therapeutic use</subject><subject>Multimodal Imaging</subject><subject>Neuroimaging</subject><subject>Pediatrics</subject><subject>Pilot Projects</subject><subject>Positron emission</subject><subject>Positron emission tomography</subject><subject>Prefrontal cortex</subject><subject>Prospective Studies</subject><subject>Regression analysis</subject><subject>Regression models</subject><subject>Sarcoma</subject><subject>Survival</subject><subject>Traumatic brain injury</subject><subject>Young Adult</subject><subject>Young adults</subject><issn>0161-5505</issn><issn>1535-5667</issn><issn>2159-662X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkd1qGzEQhUVpSNwkD9CbIuj1OtJqpd3tTXHsODEk1OTnopQitNqJLWNLqX5M8w596Mg4De3VzDBnzhz4EPpIybBsRX22smkD_ZCWbFgKUQvyDg0oZ7zgeXqPBoQKWnBO-BH6EMKKECKapjlER6zhNactG6A_E4igo7ELfGUWy2LiAuAbiEsXPfxWEYqZ7ZOGHp97ZSweL5VdQMC5nUNvVPRGY2V7_N2l7DHq0zrisbIaPL5Lfmu2zgf8EHYPfmDa4OnP6eQSzy_uz25uZ1_wCM_N2kV8F1P_fIIOHtU6wOlrPUYP04v78VVx_e1yNh5dF7qs61hwSjqqNIGOK9GWJSFNBw0nZcVaRToFVdkx3kCfYwMDqJVWqiI166jWbU3YMfq6931K3WYns9GrtXzyZqP8s3TKyP831izlwm0lpbRqeVtlh8-vDt79ShCiXLnkbQ4tGRGVaHlViayie5X2LgQPj28vKJE7gnJPUGaCck8w33z6N9vbxV9k7AVohZkq</recordid><startdate>20240601</startdate><enddate>20240601</enddate><creator>Baratto, Lucia</creator><creator>Singh, Shashi B</creator><creator>Williams, Sharon E</creator><creator>Spunt, Sheri L</creator><creator>Rosenberg, Jarrett</creator><creator>Adams, Lisa</creator><creator>Suryadevara, Vidyani</creator><creator>Iv, Michael</creator><creator>Daldrup-Link, Heike</creator><general>Society of Nuclear Medicine</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>4T-</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>M7Z</scope><scope>NAPCQ</scope><scope>P64</scope><scope>5PM</scope></search><sort><creationdate>20240601</creationdate><title>Detecting High-Dose Methotrexate-Induced Brain Changes in Pediatric and Young Adult Cancer Survivors Using [ 18 F]FDG PET/MRI: A Pilot Study</title><author>Baratto, Lucia ; Singh, Shashi B ; Williams, Sharon E ; Spunt, Sheri L ; Rosenberg, Jarrett ; Adams, Lisa ; Suryadevara, Vidyani ; Iv, Michael ; Daldrup-Link, Heike</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c277t-510b1ac0eb5a6922008be8502439a0bae42b358edcede3ee7acaa4073b1cc9703</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Blood flow</topic><topic>Brain</topic><topic>Brain - diagnostic imaging</topic><topic>Brain - drug effects</topic><topic>Brain injury</topic><topic>Cancer</topic><topic>Cancer Survivors</topic><topic>Cerebral blood flow</topic><topic>Child</topic><topic>Children</topic><topic>Cingulum</topic><topic>Clinical Investigation</topic><topic>Clustering</topic><topic>Cognition</topic><topic>Cognitive ability</topic><topic>Correlation</topic><topic>Diffusion coefficient</topic><topic>Evaluation</topic><topic>Executive function</topic><topic>Female</topic><topic>Fluorine isotopes</topic><topic>Fluorodeoxyglucose F18</topic><topic>Glucose metabolism</topic><topic>Head injuries</topic><topic>Heterogeneity</topic><topic>Hippocampus</topic><topic>Humans</topic><topic>Intelligence</topic><topic>Leukemia</topic><topic>Lymphoma</topic><topic>Magnetic Resonance Imaging</topic><topic>Male</topic><topic>Memory</topic><topic>Methotrexate</topic><topic>Methotrexate - adverse effects</topic><topic>Methotrexate - therapeutic use</topic><topic>Multimodal Imaging</topic><topic>Neuroimaging</topic><topic>Pediatrics</topic><topic>Pilot Projects</topic><topic>Positron emission</topic><topic>Positron emission tomography</topic><topic>Prefrontal cortex</topic><topic>Prospective Studies</topic><topic>Regression analysis</topic><topic>Regression models</topic><topic>Sarcoma</topic><topic>Survival</topic><topic>Traumatic brain injury</topic><topic>Young Adult</topic><topic>Young adults</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Baratto, Lucia</creatorcontrib><creatorcontrib>Singh, Shashi B</creatorcontrib><creatorcontrib>Williams, Sharon E</creatorcontrib><creatorcontrib>Spunt, Sheri L</creatorcontrib><creatorcontrib>Rosenberg, Jarrett</creatorcontrib><creatorcontrib>Adams, Lisa</creatorcontrib><creatorcontrib>Suryadevara, Vidyani</creatorcontrib><creatorcontrib>Iv, Michael</creatorcontrib><creatorcontrib>Daldrup-Link, Heike</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Docstoc</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biochemistry Abstracts 1</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of Nuclear Medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Baratto, Lucia</au><au>Singh, Shashi B</au><au>Williams, Sharon E</au><au>Spunt, Sheri L</au><au>Rosenberg, Jarrett</au><au>Adams, Lisa</au><au>Suryadevara, Vidyani</au><au>Iv, Michael</au><au>Daldrup-Link, Heike</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Detecting High-Dose Methotrexate-Induced Brain Changes in Pediatric and Young Adult Cancer Survivors Using [ 18 F]FDG PET/MRI: A Pilot Study</atitle><jtitle>Journal of Nuclear Medicine</jtitle><addtitle>J Nucl Med</addtitle><date>2024-06-01</date><risdate>2024</risdate><volume>65</volume><issue>6</issue><spage>864</spage><epage>871</epage><pages>864-871</pages><issn>0161-5505</issn><eissn>1535-5667</eissn><eissn>2159-662X</eissn><abstract>Significant improvements in treatments for children with cancer have resulted in a growing population of childhood cancer survivors who may face long-term adverse outcomes. Here, we aimed to diagnose high-dose methotrexate-induced brain injury on [
F]FDG PET/MRI and correlate the results with cognitive impairment identified by neurocognitive testing in pediatric cancer survivors.
In this prospective, single-center pilot study, 10 children and young adults with sarcoma (
= 5), lymphoma (
= 4), or leukemia (
= 1) underwent dedicated brain [
F]FDG PET/MRI and a 2-h expert neuropsychologic evaluation on the same day, including the Wechsler Abbreviated Scale of Intelligence, second edition, for intellectual functioning; Delis-Kaplan Executive Function System (DKEFS) for executive functioning; and Wide Range Assessment of Memory and Learning, second edition (WRAML), for verbal and visual memory. Using PMOD software, we measured the SUV
, cortical thickness, mean cerebral blood flow (CBF
), and mean apparent diffusion coefficient of 3 different cortical regions (prefrontal cortex, cingulate gyrus, and hippocampus) that are routinely involved during the above-specified neurocognitive testing. Standardized scores of different measures were converted to
scores. Pairs of multivariable regression models (one for
scores < 0 and one for
scores > 0) were fitted for each brain region, imaging measure, and test score. Heteroscedasticity regression models were used to account for heterogeneity in variances between brain regions and to adjust for clustering within patients.
The regression analysis showed a significant correlation between the SUV
of the prefrontal cortex and cingulum and DKEFS-sequential tracking (DKEFS-TM4)
scores (
= 0.003 and
= 0.012, respectively). The SUV
of the hippocampus did not correlate with DKEFS-TM4
scores (
= 0.111). The SUV
for any evaluated brain regions did not correlate significantly with WRAML-visual memory (WRAML-VIS)
scores. CBF
showed a positive correlation with SUV
(
= 0.56,
= 0.01). The CBF
of the cingulum, hippocampus, and prefrontal cortex correlated significantly with DKEFS-TM4 (all
< 0.001). In addition, the hippocampal CBF
correlated significantly with negative WRAML-VIS
scores (
= 0.003).
High-dose methotrexate-induced brain injury can manifest as a reduction in glucose metabolism and blood flow in specific brain areas, which can be detected with [
F]FDG PET/MRI. The SUV
and CBF
of the prefrontal cortex and cingulum can serve as quantitative measures for detecting executive functioning problems. Hippocampal CBF
could also be useful for monitoring memory problems.</abstract><cop>United States</cop><pub>Society of Nuclear Medicine</pub><pmid>38575193</pmid><doi>10.2967/jnumed.123.266760</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0161-5505 |
ispartof | Journal of Nuclear Medicine, 2024-06, Vol.65 (6), p.864-871 |
issn | 0161-5505 1535-5667 2159-662X |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11149594 |
source | MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
subjects | Adolescent Adult Blood flow Brain Brain - diagnostic imaging Brain - drug effects Brain injury Cancer Cancer Survivors Cerebral blood flow Child Children Cingulum Clinical Investigation Clustering Cognition Cognitive ability Correlation Diffusion coefficient Evaluation Executive function Female Fluorine isotopes Fluorodeoxyglucose F18 Glucose metabolism Head injuries Heterogeneity Hippocampus Humans Intelligence Leukemia Lymphoma Magnetic Resonance Imaging Male Memory Methotrexate Methotrexate - adverse effects Methotrexate - therapeutic use Multimodal Imaging Neuroimaging Pediatrics Pilot Projects Positron emission Positron emission tomography Prefrontal cortex Prospective Studies Regression analysis Regression models Sarcoma Survival Traumatic brain injury Young Adult Young adults |
title | Detecting High-Dose Methotrexate-Induced Brain Changes in Pediatric and Young Adult Cancer Survivors Using [ 18 F]FDG PET/MRI: A Pilot Study |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T15%3A31%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Detecting%20High-Dose%20Methotrexate-Induced%20Brain%20Changes%20in%20Pediatric%20and%20Young%20Adult%20Cancer%20Survivors%20Using%20%5B%2018%20F%5DFDG%20PET/MRI:%20A%20Pilot%20Study&rft.jtitle=Journal%20of%20Nuclear%20Medicine&rft.au=Baratto,%20Lucia&rft.date=2024-06-01&rft.volume=65&rft.issue=6&rft.spage=864&rft.epage=871&rft.pages=864-871&rft.issn=0161-5505&rft.eissn=1535-5667&rft_id=info:doi/10.2967/jnumed.123.266760&rft_dat=%3Cproquest_pubme%3E3064695446%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3064695446&rft_id=info:pmid/38575193&rfr_iscdi=true |